Written and maintained by CASRAI Editorial Board
Last updated
The NYHA Functional Classification—originally introduced in 1928 by the Criteria Committee of the New York Heart Association and refined through nine subsequent editions—is the global clinical standard for grading the severity of functional limitation caused by heart failure (HF) symptoms during physical activity. Across cardiology clinics, remote patient monitoring for heart failure programs, and FDA cardiovascular drug and device trials, clinicians assign patients with established heart failure into one of four dynamic classes—NYHA Class I, II, III, or IV—based on the workload threshold that provokes dyspnea, fatigue, or palpitations.
To prevent staging errors in electronic health record (EHR) documentation and clinical trial eligibility screening, cardiologists and clinical investigators must distinguish the dynamic, symptom-based NYHA Functional Classification from the unidirectional structural AHA/ACC/HFSA Heart Failure Stages (A, B, C, and D) and the acute myocardial infarction Killip Classification (Classes I–IV).
What Are the Four New York Heart Association (NYHA) Functional Classes (I–IV) for Heart Failure?
The NYHA Functional Classification is a clinician-assigned scale that evaluates how severely a patient’s cardiac pathology restricts ordinary daily physical exertion. In the 1994 9th edition of Nomenclature and Criteria for Diagnosis of Diseases of the Heart and Great Vessels, the NYHA paired its four functional classes (I–IV) with four Objective Assessment categories (A = no objective evidence of cardiovascular disease; B = minimal; C = moderately severe; D = severe objective disease).
| NYHA Class | Symptom Severity & Exertional Threshold (Official NYHA Definition) | Approximate Functional Capacity (METs & 6MWT Correlates) |
|---|---|---|
| NYHA Class I (No Limitation) |
Patients with cardiac disease but resulting in no limitation of physical activity. Ordinary physical activity does not cause undue fatigue, palpitation, dyspnea, or anginal pain. | ≥ 7.0 METs; 6-Minute Walk Distance (6MWD) typically > 450 meters |
| NYHA Class II (Slight Limitation) |
Patients with cardiac disease resulting in slight limitation of physical activity. They are comfortable at rest. Ordinary physical activity (such as climbing two flights of stairs or walking uphill) results in fatigue, palpitation, dyspnea, or anginal pain. | 5.0 to 6.9 METs; 6MWD typically 300 to 450 meters |
| NYHA Class III (Marked Limitation) |
Patients with cardiac disease resulting in marked limitation of physical activity. They are comfortable at rest. Less than ordinary activity (such as walking 1–2 blocks on level ground or dressing/showering) causes fatigue, palpitation, dyspnea, or anginal pain. (Sometimes subdivided in clinical trials into IIIa [no dyspnea at rest] and IIIb [recent dyspnea on minimal exertion].) | 2.0 to 4.9 METs; 6MWD typically 150 to 300 meters |
| NYHA Class IV (Severe Limitation / Symptoms at Rest) |
Patients with cardiac disease resulting in inability to carry on any physical activity without discomfort. Symptoms of heart failure or the anginal syndrome may be present even at rest. If any physical activity is undertaken, discomfort increases. | < 2.0 METs; 6MWD typically < 150 meters (or unable to walk) |
How Do NYHA Functional Classes (I–IV) Differ from the Structural AHA/ACC/HFSA Heart Failure Stages (A–D) and Killip Classes (I–IV)?
A foundational principle of the 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure (Heidenreich et al., Circulation 2022) is that AHA/ACC/HFSA Stages A–D and NYHA Classes I–IV are complementary, not interchangeable:
- Directionality: AHA/ACC/HFSA Stages A through D track the unidirectional structural progression of heart disease over a patient’s lifetime—once a patient develops symptomatic heart failure (Stage C), they can never revert to Stage B or Stage A, even if medical therapy completely resolves their symptoms. Instead, a Stage C patient whose symptoms resolve with diuretics and guideline-directed medical therapy (GDMT) improves dynamically from Stage C, NYHA Class III to Stage C, NYHA Class I.
- Population Scope: NYHA Functional Classes I–IV apply only to patients in AHA/ACC/HFSA Stage C or Stage D (patients with structural heart disease who have current or prior symptoms of heart failure).
- Chronic vs. Acute Infarction Setting: Whereas NYHA grades chronic ambulatory or hospitalized heart failure functional capacity, the Killip-Kimball Classification (1967) grades acute hemodynamic decompensation and pulmonary congestion on physical exam immediately following an acute myocardial infarction (AMI).
Side-by-Side Comparison: NYHA vs. 2022 AHA/ACC/HFSA Stages vs. Killip Classification
| Tier / Level | NYHA Functional Classification (Classes I–IV) | 2022 AHA/ACC/HFSA Heart Failure Stages (Stages A–D) | Killip Classification in Acute MI (Killip Classes I–IV) |
|---|---|---|---|
| Level 1 / A | Class I: Structural heart disease (Stage C) with no current exertional symptom limitation | Stage A (At Risk for HF): Risk factors (HTN, diabetes, obesity, CAD, cardiotoxin exposure) without structural disease, symptoms, or elevated biomarkers | Killip I: Acute MI with no clinical signs of heart failure (clear lungs, no S3) |
| Level 2 / B | Class II: Slight limitation; symptoms with ordinary physical activity | Stage B (Pre-HF): Asymptomatic structural heart disease (reduced LVEF, LV hypertrophy, chamber enlargement), increased filling pressures, or elevated BNP/NT-proBNP/troponin | Killip II: Mild-to-moderate acute HF: pulmonary rales/crackles in ≤50% of lung fields, S3 gallop, or elevated JVP |
| Level 3 / C | Class III: Marked limitation; symptoms with less-than-ordinary physical activity | Stage C (Symptomatic HF): Structural heart disease with current or previous symptoms of heart failure (stratified by LVEF into HFrEF ≤40%, HFmrEF 41%–49%, HFpEF ≥50%, and HFimpEF) | Killip III: Frank acute pulmonary edema with rales/crackles over >50% of both lung fields |
| Level 4 / D | Class IV: Symptoms at rest or upon any physical activity | Stage D (Advanced HF): Severe symptoms interfering with daily life and recurrent hospitalizations despite optimal GDMT, requiring evaluation for LVAD, transplant, or palliative inotropes | Killip IV: Cardiogenic shock (systolic BP < 90 mmHg with peripheral hypoperfusion, oliguria, and lactic acidosis) |
How Are NYHA Class, KCCQ-12/23, and 6MWT Used as Inclusion Criteria and Endpoints in FDA Heart Failure Trials?
In cardiovascular clinical research and telecardiology trials, NYHA Functional Class governs both trial enrollment and therapy indication labeling (for example, cardiac resynchronization therapy [CRT], implantable cardioverter-defibrillators [ICDs], SGLT2 inhibitors, and transcatheter mitral/tricuspid valve interventions typically specify NYHA Class II–IV inclusion boundaries). However, because clinician-assessed NYHA class suffers from modest inter-rater reliability (concordance often 54%–60% between two cardiologists evaluating NYHA II vs. III) and coarse 4-level granularity, the U.S. Food and Drug Administration (FDA) Center for Drug Evaluation and Research (CDER) and Center for Devices and Radiological Health (CDRH) pair NYHA class with standardized ePRO clinical trials and performance endpoints:
- Kansas City Cardiomyopathy Questionnaire (KCCQ-23 and KCCQ-12): Developed by Spertus and colleagues (2000) and qualified by the FDA as a Medical Device Development Tool (MDDT) and clinical outcome assessment (COA), the 23-item KCCQ and 12-item short form (KCCQ-12) quantify Physical Limitation, Symptom Frequency/Severity, Quality of Life, and Social Limitation on a 0 to 100 scale (where 100 = best health status, 0–24 = very poor to poor, 25–49 = poor to fair, 50–74 = fair to good, and 75–100 = good to excellent). The established within-patient Minimal Clinically Important Difference (MCID) is 5 points, with changes of 10 and 20 points representing moderate-to-large and large clinical improvements.
- 6-Minute Walk Test (6MWT): An objective electronic performance outcome (ePerfO) measuring the distance walked on a flat 30-meter corridor in 6 minutes (MCID typically 25 to 35 meters in chronic heart failure).
- Hierarchical Win-Ratio Composite Endpoints: Modern Phase III heart failure trials (such as ATTR-ACT, EMPULSE, and transcatheter valve trials) frequently use the Finkelstein-Schoenfeld hierarchical win ratio combining (1) time to all-cause mortality, (2) frequency of heart failure hospitalizations, and (3) change from baseline in KCCQ Overall Summary Score (OSS) or Clinical Summary Score (CSS).
Frequently Asked Questions
What are the four New York Heart Association (NYHA) Functional Classes (I–IV) for heart failure?
The four NYHA Functional Classes grade heart failure symptom severity during physical activity: Class I indicates no limitation of physical activity (ordinary activity causes no dyspnea or fatigue); Class II indicates slight limitation (comfortable at rest, but ordinary activity causes symptoms); Class III indicates marked limitation (comfortable at rest, but less-than-ordinary activity causes symptoms); and Class IV indicates inability to carry out any physical activity without discomfort, with heart failure symptoms present even at rest.
How do NYHA Functional Classes (I–IV) differ from the structural AHA/ACC/HFSA Heart Failure Stages (A–D) and Killip Classes (I–IV)?
NYHA Classes I–IV dynamically measure current exercise intolerance and can improve or worsen over time in patients who already have symptomatic heart failure (Stages C and D). By contrast, the 2022 AHA/ACC/HFSA Stages A–D measure irreversible structural disease progression (Stage A: at risk; Stage B: pre-heart failure; Stage C: symptomatic heart failure; Stage D: advanced refractory heart failure), while Killip Classes I–IV stratify acute pulmonary edema and cardiogenic shock immediately after an acute myocardial infarction.
How are NYHA class, KCCQ-12/23, and 6MWT used as inclusion criteria and endpoints in FDA heart failure trials?
In FDA heart failure drug and device trials, NYHA Class (typically Class II–III or II–IV) is used as a baseline inclusion criterion and stratification factor, while the patient-reported Kansas City Cardiomyopathy Questionnaire (KCCQ-23 or KCCQ-12, scored 0–100 with a 5-point MCID) and the objective 6-Minute Walk Test (6MWT) serve as primary or key secondary efficacy endpoints capable of supporting FDA labeling claims for functional improvement.
